- Document Number:
20160374319
- Appl. No:
15/103457
- Application Filed:
December 10, 2014
- نبذة مختصرة :
A transgenic non-human mammal has a genome that includes an early-immediate enhancer of human cytomegalovirus (CMV enhancer), a β-actin promoter and the entire gene region of human matrix metalloproteinase 2 (hMMP2) disposed downstream of the promoter. The hMMP2 is systemically expressed in the transgenic non-human mammal, which thus provides a suitable animal model for studying chronic obstructive pulmonary disease and related diseases and conditions.
- Claim:
1. A transgenic (TG) non-human mammal having a genome that comprises an early-immediate enhancer of human cytomegalovirus (CMV enhancer), a β-actin promoter and the entire gene region of human matrix metalloproteinase 2 (hMMP2) disposed downstream of the promoter, wherein the hMMP2 is systemically expressed in the TG non-human mammal.
- Claim:
2. (canceled)
- Claim:
3. The TG non-human mammal according to claim 1, wherein the non-human mammal is a mouse.
- Claim:
4. A method for producing a transgenic (TG) non-human mammal, comprising: providing an hMMP2 expression construct that includes an early-immediate enhancer of human cytomegalovirus (CMV enhancer) and the entire gene region of human matrix metalloproteinase 2 (hMMP2) downstream of a β-actin promoter, introducing the hMMP2 expression construct into a fertilized egg, implanting said fertilized egg in a non-human mammal and allowing said fertilized egg to develop in the non-human mammal.
- Claim:
5. The method for producing the TG non-human mammal according to claim 4, wherein an offspring from said fertilized egg is raised as a founder candidate individual, genomic DNA is extracted from tissues of the founder candidate individual, and the presence of the hMMP2 expression construct in the extracted genomic DNA is ascertained.
- Claim:
6. (canceled)
- Claim:
7. The method for producing the TG non-human mammal according to claim 4, wherein the non-human mammal is a mouse.
- Claim:
8. A method for producing an animal model for developing a disease selected from the group consisting of chronic obstructive pulmonary disease (COPD), pulmonary fibrosis, airway remodeling and pulmonary hypertension, the method comprising: of administering an inducer to the TG non-human mammal according to claims 1, wherein the inducer is cigarette smoke, a cigarette smoke extract, a cigarette component, bleomycin or albumin.
- Claim:
9. A method for producing an animal model for developing a disease selected from the group consisting of chronic obstructive pulmonary disease (COPD), pulmonary fibrosis, airway remodeling and pulmonary hypertension, the method comprising: administering an inducer to the TG non-human mammal according to claim 3, wherein the inducer is cigarette smoke, a cigarette smoke extract, a cigarette component, bleomycin or albumin.
- Claim:
10. The method for producing the TG non-human mammal according to claim 5, wherein the non-human mammal is a mouse.
- Claim:
11. The TG non-human mammal according to claim 1, wherein the CMV enhancer is upstream of the β-actin promoter.
- Claim:
12. The TG non-human mammal according to claim 11, wherein the β-actin promoter is a chicken β-actin promoter that is operably linked to the hMMP2 via a rabbit β-globin.
- Current International Class:
01; 12; 12
- الرقم المعرف:
edspap.20160374319
Processing Request
No Comments.